On 14 April 2026, Johnson & Johnson raised its quarterly dividend 3.1% from $1.30 to $1.34 per share — an indicated annual rate of $5.36, up from $5.20, and the 64th consecutive year of increases. That streak is one of the longest in corporate history and it is the reason this company appears in nearly every dividend portfolio ever constructed.
This article explains what the record actually proves, what it costs a European investor to own it directly, and the fund route that captures the same trait without the single-stock exposure. Verified August 2026.
The dividend facts
| Item | Detail |
|---|---|
| Quarterly dividend | $1.34 (raised April 2026 from $1.30) |
| Indicated annual rate | $5.36 per share |
| Increase | +3.1% |
| Consecutive years of increases | 64 |
| Approximate yield | ~2.5–3%, depending on price |
| Status | Dividend King (50+ years) |
What a 64-year streak actually proves
Streaks are the most over-interpreted statistic in dividend investing, so it is worth being precise about what this one does and does not establish.
For the bigger picture, start with our best dividend ETFs hub.
What it proves: institutional discipline. Sixty-four years spans the Cuban Missile Crisis, the 1970s inflation, the 1987 crash, the dot-com unwind, the global financial crisis, a pandemic and the 2022 rate shock. A company that raised its payout through all of them has a capital-allocation culture that survives individual management teams, a business generating genuinely durable cash, and a board that treats the dividend as a commitment rather than a residual. That is a real signal about corporate character, and it is not available from a screen of current yields.
What it does not prove: that the next 64 years look like the last. Streaks create their own pressure — a company with a 64-year record faces enormous reputational cost in breaking it, which is a reason to expect the payout to continue and also a reason to watch whether it is being maintained out of strength or out of stubbornness. The relevant discipline is to check the payout ratio and free cash flow coverage rather than the streak length, because the streak tells you about the past and the coverage tells you about the future.
What the recent increases signal: a 3.1% raise is roughly inflation-matching, not inflation-beating. The streak is intact; the growth rate has moderated to something that preserves purchasing power rather than expanding it. For an income investor that distinction matters more than the headline count.
Building a dividend income stream? Start with the free portfolio sheet.
The Dividend Portfolio Starter Sheet: yields, payout calendars and the withholding-tax checklist for EU investors.
The business behind the payout
J&J today is a pharmaceutical and medical-technology company — the consumer-health business was separated out, which changed the profile meaningfully. What remains is higher-margin, higher-growth and considerably more exposed to the two risks that define large pharmaceutical companies.
Patent cliffs. A pharmaceutical company’s revenue is a portfolio of temporary monopolies. When a major drug loses exclusivity, biosimilar or generic competition can remove the majority of its revenue within a few years. Every large pharma balance sheet is a race between the drugs going off patent and the pipeline replacing them, and that race is the single most important thing to track — far more than the dividend history.
Litigation. J&J has carried substantial, well-publicized legal exposure related to product liability, with provisions and settlement structures that have run into the billions. Litigation risk is genuinely hard for an outside investor to price, moves in large discrete steps, and is one of the clearest arguments against holding any single pharmaceutical company at meaningful weight.
The counterweight: medical technology provides a more stable, less patent-dependent revenue base, the balance sheet is among the strongest in the corporate world, and the scale of the pipeline gives it more shots on goal than almost any competitor. This is a high-quality business with identifiable, large, discrete risks — which is exactly the profile that argues for owning it inside a fund.
The European investor’s practical problem
Buying J&J shares directly from Europe works technically and costs more than it looks.
Withholding tax. The US withholds 15% on dividends paid to European residents under most treaties (30% without the correct broker paperwork), and then your own country taxes the distribution again with variable credit for what was already taken. The net yield on a ~2.5–3% gross payout can land closer to 1.8–2.2% depending on your jurisdiction — a substantial haircut on the entire reason for owning it.
US estate tax. Directly-held US shares are US-situs assets, exposed above a modest non-resident threshold. Most European retail investors have never heard of this and it is a real, documented exposure.
Currency and single-stock risk. The dividend arrives in dollars, converted by your broker at their rate, and one company’s litigation outcome can move a fifth of your income stream.
The alternative that solves all three: an Irish-domiciled UCITS fund holding J&J alongside hundreds of comparable companies accesses the treaty rate at fund level, removes the estate-tax question entirely, and diversifies the litigation and patent risk. The income pillar maps the shelf, and the dividend aristocrats fund screens for precisely the trait — long payout-growth records — that brought you to this article.
Sizing, if you buy it anyway
The rules this site applies to any single stock inside an income portfolio: maximum 2–3% of the total, with all single-stock positions summed under one ceiling of roughly 10–15%; no position sized so that a dividend cut or a litigation headline changes your spending plans; and the fund layer built first, with single names as deliberate additions rather than the foundation. An investor whose income depends on three or four individual companies has built a portfolio whose worst outcome is a single board meeting away.
Reader scenarios
“I want the safest dividend in the world.” There is no such thing, and a 64-year streak is the closest available proxy. It is still one company with patent cliffs and litigation. The safest dividend available to a European investor is a diversified fund’s distribution, which cannot be cut by one board.
“The yield looks low.” It is, deliberately — quality-income companies typically yield 2–3% and grow the payout, while 6% yields typically come with something wrong. The critique article explains the trade-off in full.
“Should I hold it in a savings plan?” Regular purchases of a single US stock from Europe mean repeated currency conversion charges, which frequently exceed a fund’s entire annual fee. A fund with a euro line is materially cheaper to accumulate.
Quick-start checklist
- Read the payout ratio and cash-flow coverage, not the streak length.
- Compute the after-withholding yield for your country before deciding.
- Check your US estate-tax exposure if you hold US shares directly.
- Cap any single stock at 2–3% and sum all of them under one ceiling.
- Build the fund layer first — it captures the same trait without the litigation risk.
Verdict
Sixty-four consecutive annual increases is a genuine, rare signal of corporate discipline, and Johnson & Johnson deserves its place in the small group of businesses that have demonstrated it. What the streak does not do is remove patent cliffs, litigation exposure, US withholding tax, estate-tax questions or the plain fact that this is one company. For a European income investor, the trait is worth owning and the vehicle for owning it should almost always be a fund. Buy the stock if you want the specific business at 2–3%; buy the aristocrats screen if what you actually wanted was the discipline the streak represents.
The Dividend Kings, and what membership is worth
Fewer than sixty American companies have raised their dividend for fifty consecutive years or more, and Johnson & Johnson’s sixty-four places it near the top of that list. The group is worth understanding as a category because it is the reference set behind every dividend-growth fund on Europe’s shelf.
What the Kings share is not an industry — the list spans consumer staples, industrials, utilities and healthcare — but a corporate culture in which the dividend is a governing constraint rather than a discretionary output. Management teams at these companies allocate capital knowing the increase must happen, which imposes a discipline that shows up in balance-sheet conservatism, in reluctance to over-acquire, and in a resistance to the empire-building that destroys shareholder value elsewhere. Research on payout policy has consistently found that companies committing to distributions invest more selectively than those that do not.
What the Kings do not share is superior forward returns. Membership is a backward-looking award, and the historical record of dividend-growth strategies is good rather than spectacular — they have tended to deliver market-like returns with lower drawdowns and materially better behaviour from their holders, which is a genuinely valuable combination and not the same as outperformance.
The practical translation for a European investor: the trait is worth owning, and the efficient way to own it is the screen rather than the individual member. A dividend-aristocrat fund holds the whole cohort, rebalances as companies join and leave, and cannot have its income halved by a single adverse court ruling.
Reading a payout ratio properly
The most useful number on a dividend stock is not the yield or the streak — it is the coverage, and there are three ways to measure it that give different answers.
Against reported earnings. The standard calculation, and the one most easily distorted. Large one-off charges — litigation provisions, impairments, restructuring — can push a reported payout ratio above 100% in a year when the business generated ample cash. For a company carrying substantial legal provisions this measure is regularly misleading.
Against adjusted earnings. What the company reports and what analysts cite. Reasonable, and worth remembering that the adjustments are chosen by the same management team whose dividend record is at stake.
Against free cash flow. The most honest measure: cash from operations minus capital expenditure, compared against dividends paid. This is the number that determines whether the payout is being funded by the business or by the balance sheet, and it is where a deteriorating dividend shows stress first.
The pattern to watch across all three is the trend rather than the level. A payout ratio drifting upward year after year means dividends are growing faster than the earnings behind them — sustainable for a while, and the mechanism by which long streaks eventually end.
Frequently asked questions
How much is the J&J dividend in 2026?
$1.34 per share quarterly after the April 2026 increase — an indicated annual rate of $5.36, up 3.1% from $5.20.
How many years has J&J raised its dividend?
64 consecutive years as of 2026, placing it firmly among the Dividend Kings — companies with 50 or more consecutive annual increases.
What is the J&J dividend yield?
Roughly 2.5–3% depending on the share price on the day — typical for a quality-income company that grows its payout rather than maximizing it.
What tax do I pay as a European holder?
15% US withholding under most treaties with the correct broker paperwork (30% without), then your own country’s tax on the distribution with variable credit. The net yield is materially below the gross.
Is the dividend safe?
The coverage and balance sheet are strong, and the reputational cost of breaking a 64-year streak is enormous. The real risks are patent cliffs and litigation, both of which move in large discrete steps.
Is there a fund that holds J&J?
Every world and US index fund holds it, and the dividend-aristocrat and quality-income screens hold it at higher weight — capturing the payout-growth trait with the single-company risk diversified away.
What is a Dividend King?
A company with 50 or more consecutive years of dividend increases — fewer than sixty US companies qualify, and J&J’s 64 years places it near the top of the list.
Do Dividend Kings outperform?
Not reliably. The historical record is market-like returns with lower drawdowns and better holder behaviour — genuinely valuable, and not the same as outperformance.
Which payout ratio should I use?
Free cash flow coverage — cash from operations minus capex against dividends paid. Reported-earnings ratios are distorted by litigation provisions and impairments.
What is the warning sign in a long streak?
A payout ratio drifting upward year after year: dividends growing faster than the earnings behind them. That is how long streaks eventually end.
Why did J&J separate its consumer business?
To focus on higher-margin pharmaceuticals and medical technology. The remaining business grows faster and carries more patent-cliff exposure.
Is 3.1% a good increase?
It roughly matches inflation rather than beating it — the streak is intact, the growth rate has moderated, and for an income investor that distinction matters more than the count.
Cited sources: Johnson & Johnson investor relations, SEC filings, and The dividend ETF pillar. Verify current fund figures before investing. Educational content, not financial advice.
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →